Special 510(k) Summary: Device Modification to the Asnis III Cannulated Screw System

Submission Information

Name and Address of the Sponsor

of the 510(k) Submission:

Howmedica Osteonics Corp

59 Route 17

Allendale, NJ 07401-1677

DEC 2 0 2002

KO24060 page 1 of 1

Contact Person:

Karen Ariemma

Regulatory Affairs Specialist

Date of Summary Preparation:

December 6, 2002

Device Identification

Proprietary Name:

Asnis III Cannulated Screw System

Common Name:

Bone Screw

Classification Name and Reference: Single/multiple component metallic bone fixation appliances and accessories, 21 CFR §888.3030

This Special 510(k) submission is intended to address design modifications to the Asnis III Cannulated Screw System. Additional lengths have been added to the 8.0 mm diameter screws. The core thread diameter of the 6.5 mm diameter screws has been modified. The material, intended use, packaging and sterilization of the subject devices are identical to those of predicate devices.

Intended Use

The intended use of the modified devices, as described in its labeling, has not changed as a result of this modification. These devices are intended for fracture fixation of small and long bones and of the pelvis. The system is not intended for spinal use.

Statement of Technological Comparison

Mechanical testing and analysis demonstrates comparable properties of the subject to the predicate device.



DEC 2 0 2002

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Karen Ariemma Regulatory Affairs Specialist Stryker Howmedica Osteonics Corp. 59 Route 17 South Allendale, New Jersey 07401-1677

Re: K024060

Trade Name: Asnis III Cannulated Screw System

Regulation Number: 21 CFR 888.3030

Regulation Name: Single/multiple component metallic bone fixation appliances and

accessories

Regulatory Class: II Product Code: HWC Dated: December 6, 2002 Received: December 9, 2002

Dear Ms. Ariemma:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

for Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Miriam & Provost

Enclosure

Device Name: Asnis I	II Cannulated Screv	v System			
Indications for Use					
The Asnis III Cannulat the pelvis. The system			acture fixation o	f small and long b	ones and of
(PLEASE DO NOT NEEDED)	WRITE BELOW	THIS LINE	E-CONTINUE	ON ANOTHER	PAGE IF
Con	ncurrence of CDRH	, Office of L	Device Evaluatio	on (ODE)	
Prescription Use X	О	R	Over-T	he-Counter Use_	
(Per 21 CFR 801.109)	1		(Optional Form	nat 1-2-96)	

510(k) Number (if known): <u>K</u>O24060

Muran C. Provost
(Division Sign-Off)
Division of General, Restorative and Neurological Devices

1100 Number K 624060